ASCENT-GYN-01 | CT06486441

Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy. Contact: trials@anzgog.org.au

ASCENT-GYN-01 | CT064864412026-06-24T22:18:27+10:00

GLORIOSA | NCT05445778

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer. Contact: GLORIOSA@anzgog.org.au 

GLORIOSA | NCT054457782026-06-24T22:21:40+10:00

Symbiotic-GYN-18 | NCT07578649

An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent Mismatch Repair (MMR) Proficient Endometrial Cancer. Contact: [...]

Symbiotic-GYN-18 | NCT075786492026-06-24T22:28:02+10:00

DESTINY-Ovarian01 | NCT06819007

A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing, Homologous-Recombination Deficiency Negative Ovarian Cancer. Contact: DESTINY-Ov01@anzgog.org.au

DESTINY-Ovarian01 | NCT068190072026-06-24T21:48:16+10:00

FRAmework-01 | NCT07213804

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer. Contact: FRAMEWORK-01@anzgog.org.au

FRAmework-01 | NCT072138042026-06-24T21:43:38+10:00

RAINFOL-07 | NCT07564141

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator’s Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer. Contact: RAINFOL-07@anzgog.org.au

RAINFOL-07 | NCT075641412026-06-24T21:41:05+10:00

RAINFOL-04 | NCT07225270

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy. Contact: RAINFOL-04@anzgog.org.au

RAINFOL-04 | NCT072252702026-06-24T21:37:42+10:00

RAINFOL-03 | NCT07166094

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer. Contact: RAINFOL-03@anzgog.org.au

RAINFOL-03 | NCT071660942026-07-09T06:49:18+10:00

RAINFOL-02 | NCT06619236

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer. Contact: RAINFOL-02@anzgog.org.au

RAINFOL-02 | NCT066192362026-07-09T06:49:42+10:00

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812026-07-09T06:49:30+10:00

HOME

We acknowledge the Traditional Custodians of the lands across Australia on which we live, learn and work and pay respect to Elders past, present and future, acknowledging their continuing connection to land, sea and community.

We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi.

Australia New Zealand Gynaecological Oncology Group www.anzgog.org.au

Level 6, Lifehouse, 119-143 Missenden Road Camperdown NSW 2050 T:+61 2 8071 4880

E: contact@anzgog.org.au © 2026 ANZGOG | Copyright | Disclaimer | ANZGOG Policies | Whistleblower

Go to Top